Discover and read the best of Twitter Threads about #RheumRibbonPanel
Most recents (2)
Time for a massive #RheumMadness thank you thread. This was a HUGE endeavor with so many contributors!
First, massive thanks to ALL OF YOU for participating! This project was always about inspiring collaborative learning. Thanks for playing, learning, debating, and sharing!
First, massive thanks to ALL OF YOU for participating! This project was always about inspiring collaborative learning. Thanks for playing, learning, debating, and sharing!
Second, huge thanks to the @RheumResearch Foundation for supporting this project through the Clinician Scholar Educator award. All aspiring educators in rheumatology, consider applying for this award! It connects you with an amazing community of educators.
Third, thank you to the fellow/resident members of the #RheumMadness leadership team: @AkiUdupa @GuyKatzMD @didemsayginmd and Allen Witt. It took a special kind of bravery to join this team and educate others on a podcast. You all are amazing!
How well did the #RheumRibbonPanel match #RheumMadness participants' predictions in the #SeronegativeSixteen?
Belimumab for LN vs. Anifrolumab
👩⚖️Panel:
Belimumab for LN: 5
Anifrolumab: 2
👩💻Participants:
80% picked belimumab for LN
More in 🧵 below 👇 (1/8)
Belimumab for LN vs. Anifrolumab
👩⚖️Panel:
Belimumab for LN: 5
Anifrolumab: 2
👩💻Participants:
80% picked belimumab for LN
More in 🧵 below 👇 (1/8)
PEXIVAS vs. Avacopan
👩⚖️Panel:
PEXIVAS: 3
Avacopan: 4
👩💻Participants:
66% picked avacopan
(2/8)
👩⚖️Panel:
PEXIVAS: 3
Avacopan: 4
👩💻Participants:
66% picked avacopan
(2/8)
IgG4-RD Classification Criteria vs. RP Subtypes
👩⚖️Panel:
IgG4-RD Classification Criteria: 5
RP Subtypes: 2
👩💻Participants:
77% picked IgG4-RD Classification Criteria
(3/8)
👩⚖️Panel:
IgG4-RD Classification Criteria: 5
RP Subtypes: 2
👩💻Participants:
77% picked IgG4-RD Classification Criteria
(3/8)
